Is the fourth-generation targeted drug Brigatinib/Brigatinib launched in China?

Brigatinib/Brigatinib (Brigatinib) is a second-generation targeted drug, not a fourth-generation. Brigatinib/Brigatinib is a first-line treatment option for patients with ALKfusion-positive NSCLC. Results from a clinical trial (ALTA-1L) suggest that brigatinib/brigatinib may provide longer progression-free survival (median) compared with standard first-line treatment (crizotinib) PFS) and overall survival (median OS), while reducing the risk of tumor progression. Therefore, Brigatinib/Brigatinib has important clinical application value in the first-line treatment of ALKfusion-positive NSCLC.

For patients with NSCLC who have received other ALK inhibitors and developed resistance, brigatinib/brigatinib remains an important treatment option. The results of the clinical trial (ALTA) showed that Brigatinib/Brigatinib showed a higher overall response rate and longer progression-free survival in these drug-resistant patients. In addition, for some common ALK resistance mutations, such as the T790M mutation of ALK, brigatinib also shows certain anti-tumor effects.

Brigatinib/Brigatinib has been launched in China and has been included in medical insurance. Since it has just been approved for marketing, patients may not be able to buy it in domestic pharmacies. If you need to purchase it in China, please consult the local pharmacy. However, the price is quite high, more than 10,000 yuan. foreignBrigatinib/BrigatinibIt is mainly a generic drug, mainly from Bangladesh and Laos. The price of the international version of the Bangladeshi generic drug Yaopin is about About 2000 yuan, the specification is 90mg*30 tablets; the price of the Laos version of the generic drug is about 600, and the specification is smaller. And the ingredients of domestic original drugs and foreign generic drugs are basically the same.